BDSX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Biodesix Inc (BDSX) is not a clear buy right now for a beginner long-term investor with $50,000-$100,000 and impatience about waiting for better entry points. The stock has bullish momentum and positive analyst sentiment, but the lack of recent news, no strong proprietary buy signal, and insider selling make this more of a hold than an immediate long-term buy. If forced to choose today, it is a moderate-quality hold rather than a strong buy.
BDSX is in a short-term uptrend. Price closed at 16.46, above the prior close of 15.99, with a strong 7.97% daily gain and additional post-market strength of 2.97%. MACD histogram is positive and expanding, which supports momentum continuation. The moving averages are bullish with SMA_5 > SMA_20 > SMA_200, confirming trend strength. RSI_6 at 73.825 shows the stock is getting stretched, so while momentum is strong, the current price is no longer an obvious low-risk entry. Key levels to watch are pivot 14.897, resistance 16.032/16.732, and support 13.762/13.062. Overall, trend is bullish but somewhat extended.
["Canaccord raised the price target to $22 from $20 and kept a Buy rating.", "The target increase was driven by higher revenue assumptions and margin expansion expectations.", "Hedge funds are buying, with buying amount up 1991.20% over the last quarter.", "Technical trend is bullish with SMA_5 > SMA_20 > SMA_200 and a positive expanding MACD histogram.", "Options data shows bullish sentiment through 0.0 put-call ratios.", "Stock gained 7.97% in regular trading and added another 2.97% after hours."]
["Insiders are selling, with selling amount up 531.80% over the last month.", "No news in the recent week, so there is no fresh event-driven catalyst.", "RSI is elevated at 73.825, indicating the stock is somewhat extended after the recent move.", "No recent congress trading activity was reported.", "No financial snapshot was available, so latest quarter growth cannot be confirmed."]
Latest quarter financials were not available because the financial snapshot returned an error. Because of that, I cannot confirm the most recent quarterly growth trends or season. For a long-term beginner investor, this limits confidence in the fundamental case even though the market is currently rewarding the stock on momentum and analyst optimism.
The analyst trend is positive. On 2026-05-05, Canaccord raised its price target to $22 from $20 and maintained a Buy rating, citing increased revenue assumptions and operating margin expansion in its 10-year DCF model. This is a constructive Wall Street view, but the pros are balanced by insider selling and the absence of fresh company news.
